Cite
HARVARD Citation
Seto, T. et al. (2021). Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study. Cancer science. 112 (4), pp. 1556-1566. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Seto, T. et al. (2021). Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study. Cancer science. 112 (4), pp. 1556-1566. [Online].